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Summary
Background.— Cigarette smoking, raised blood pressure, unfavourable lipid concentrations,
diabetes and — more indirectly — obesity, are responsible for most coronary heart diseasefactors;
Coronary heart
disease;
Dyslipidaemia;
events in developed and developing countries.
Aims.— The objective of our study was to compare prevalence, treatment and control of car-
diovascular risk factors in two samples of men with stable coronary heart disease, recruited in
France and Spain.
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artérielle
patients coronariens, en France comme en Espagne, mais la répartition des facteurs de risque
est différente selon le pays. Une proportion importante de patients est insufﬁsamment con-
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Abbreviations
ACE angiotensin-converting enzyme
ARA II angiotensin II receptor antagonist
BMI body mass index
CHD coronary heart disease
HDL high-density lipoprotein
LDL low-density lipoproteinBackground
Understanding the crucial role of cardiovascular risk fac-
tors has established new paradigms in the epidemiological
approach to CHD. In the past decades, many potential new
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recursors of CHD have been identiﬁed, such as thrombotic,
nﬂammatory or genetic factors, infectious agents, early life
xposures, oestrogen deﬁciency and psychosocial factors
1]. However, cigarette smoking and traditional risk factors
raised blood pressure, unfavourable lipid concentrations,
iabetes and obesity [which is linked more indirectly to car-
iovascular risk]), partially promoted by inappropriate diet
nd physical inactivity, are the most prevalent cardiovascu-
ar risk factors in both developed and developing areas of the
orld, and also have the highest impact on CHD incidence
2—5].nch and Spanish men with CHD 81
Methods.— Standardized measurements of body mass index, systolic and diastolic blood pres-
sures, plasma lipids, glycaemia, and smoking were collected and drug use was registered.
Cross-sectional comparisons were made between French and Spanish samples.
Results.— Data from 982 individuals were analysed (420 French and 562 Spanish men). Current
smoking was more frequent in Spain (p < 0.001), whereas hypertension and uncontrolled blood
pressure were more frequent in France (p < 0.001). Mean concentrations of low-density lipopro-
tein cholesterol and triglycerides were signiﬁcantly higher in France (p < 0.001). No signiﬁcant
differences were observed regarding obesity, high-density lipoprotein cholesterol and diabetes.
More than 97% of participants presented with at least one of the following conditions: hyper-
tension, dyslipidaemia, diabetes, obesity or smoking. Antiplatelet agents, calcium inhibitors,
diuretics and hypoglycaemic drugs were used more frequently in France, whereas angiotensin-
converting enzyme inhibitors and lipid-lowering treatments were used more frequently in Spain.
Conclusion.— Prevalence of cardiovascular risk factors is high among French and Spanish
patients with stable coronary heart disease, with differences between countries regarding
the distribution of the various risk factors. A great proportion of patients do not reach the
recommended levels for risk factor control.
© 2009 Elsevier Masson SAS. All rights reserved.
Résumé
Contexte.— Le tabagisme, l’hypertension artérielle, les dyslipidémies, le diabète et plus indi-
rectement, l’obésité sont à l’origine de la plupart des événements coronariens.
Objectifs.— Le but de ce travail était de comparer la prévalence, les traitements et le contrôle
des facteurs de risque cardiovasculaire, dans une population d’hommes coronariens, recrutés
en France et en Espagne.
Méthodes.— Des mesures standardisées de l’indice de masse corporelle, de la pression sanguine
artérielle, des lipides plasmatiques, de la glycémie et du tabagisme ont été réalisées et les
traitements médicamenteux ont été recueillis.
Résultats.— Un groupe de 982 patients de sexe masculin a été constitué (420 franc¸ais et
562 espagnols). Le tabagisme actif était plus fréquent en Espagne (p < 0,001), l’hypertension et
le non-contrôle des chiffres de pression sanguine artérielle se rencontraient plus fréquemment
en France (p < 0,001). Les niveaux plasmatiques moyens de cholestérol-LDL et de triglycérides
étaient plus élevés en France (p < 0,001). Aucune différence signiﬁcative n’a été mise en évi-
dence sur l’obésité, le cholestérol-HDL ou le diabète. Plus de 97% des patients présentaient
une hypertension, une dyslipidémie, un diabète, une obésité ou un tabagisme. Les médicaments
antiagrégants plaquettaires, inhibiteurs calciques, diurétiques et hypoglycémiants étaient plus
fréquemment utilisés en France. Les inhibiteurs de l’enzyme de conversion de l’angiotensine
et les hypolipémiants étaient plus fréquents en Espagne.
Conclusion.— La prévalence des facteurs de risque cardiovasculaire est élevée parmi lesThe literature has often reported that major cardiovas-
ular risk factors can only explain half of the burden of CHD
ncidence, based on the observation that many individuals
ith signiﬁcant levels of cardiovascular risk factors never
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xperience CHD events and, conversely, that some individu-
ls with CHD lack any of the major cardiovascular risk factors
6—8]. However, this hypothesis is no longer supported by
pidemiological studies, which show that only 15—20% of
table CHD patients lack all of the major cardiovascular
isk factors [9,10]. These major modiﬁable risk factors are
argely uncontrolled [11—14].
Populations in Southern Europe, where the incidence and
ortality from CHD is low, have shown a prevalence of tra-
itional cardiovascular risk factors close to the prevalence
bserved in countries characterized by much higher CHD
ncidence and mortality [15,16]. France and Spain are two
djacent Southern European countries that share high life
xpectancy [17] despite different lifestyle habits, dietary
atterns and healthcare systems. Treatments and hospital-
zations for acute coronary syndromes are funded entirely by
he national healthcare system in each country. However,
hile expenditures for secondary prevention treatments
nd complementary tests are covered totally by the French
ystem, with no prepayment required from patients, the
panish healthcare system pays for secondary prevention
rugs only in patients older than 65 years, whereas younger
atients are partially reimbursed.
Data on cardiovascular risk factors at discharge after
cute myocardial infarction have already been reported in
rance and Spain [14,18,19], but prevalence and long-term
anagement of cardiovascular risk factors in individuals
ith stable CHD have not been studied in detail, especially
ith regard to lipid disorders. The aim of the present study
as to compare prevalence, treatment and control of car-
iovascular risk factors in two samples of men with stable
HD recruited in France and Spain.
ethods
opulation setting
his analysis was designed to compare the prevalence of
ardiovascular risk factors in individuals with stable CHD
iving in two regions of South-West Europe: France and
pain. In France, participants were recruited as part of
he Génétique et Environnement en Europe du Sud (GENES)
tudy, a case-control study designed to assess the role of
ene—environment interactions in the occurrence of CHD.
articipants were men living in the Toulouse area (Haute-
aronne, South-West France, bordering on Spain), a region
f 1.1million inhabitants (540,000men). Participants were
ncluded from 2001 to 2004. For the present analysis,
nly cases with a history of acute myocardial infarction
ere taken into account. Eligible participants were French
ale CHD patients, aged 45—74 years, living in the area
f Toulouse and hospitalized in the Toulouse University
ospital for follow-up of stable CHD. Prior acute myocar-
ial infarction had to be documented in the medical ﬁle
f the patient and be determined from evidence of new
athological Q-waves on electrocardiogram, imaging evi-
ence of healed acute myocardial infarction or evidence
f a region of loss of viable myocardium that was thinned
nd failed to contract, in the absence of a non-ischaemic
ause. Patients with conﬁrmed acute myocardial infarc-
ion, electrocardiogram changes or rise in cardiac enzymes
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> 1.5 times the upper limit) in the past 2months, were
xcluded.
In Spain, the Registre Gironi del Cor Project (REGICOR)
ecords all acute myocardial infarctions occurring in local
nhabitants in six counties in Gerona. This province is located
n North-East Spain, bordering on France, with a refer-
nce population of approximately 600,000 subjects. The
egistry process is done prospectively, and encompasses
hose patients admitted to the only referral hospital in the
rea. In order to be eligible, subjects have to be clinically
iagnosed with acute myocardial infarction. Once identi-
ed, patients are classiﬁed according to the MONItoring of
rends and determinants in CArdiovascular diseases (MON-
CA) project algorithm, which takes into account type of
ymptoms, electrocardiogram ﬁndings and enzymes [20].
elected patients were part of the deﬁnite non-fatal acute
yocardial infarction group, deﬁned as: deﬁnite electro-
ardiogram; or typical, atypical or inadequately described
ymptoms, together with probable electrocardiogram and
bnormal enzymes; or typical symptoms and abnormal
nzymes with ischaemic or non-codeable electrocardiogram
r electrocardiogram not available [20,21]. The inclusion
eriod lasted between 1995 and 2004, although 75% of
atients were recruited after 2001. A 6-month follow-up was
one to measure blood lipid concentrations in patients with
table status.
In summary, men aged 45—74 years, with stable CHD,
ho reported a history of acute myocardial infarction were
elected in both studies for the purpose of our analysis. The
ample size (420 and 562 individuals in France and Spain,
espectively), allowed us to detect differences between
entres in the prevalence of cardiovascular risk factors of
reater than 10 percentage-points, with a statistical power
f at least 87.5%. Authorization from the local ethics com-
ittees was obtained in accordance with the French and
panish laws and the Declaration of Helsinki. All participants
ere informed about the aim of the study and informed
onsent was signed by each subject.
uestionnaires
ge and socioeconomic variables were collected through
tandardized interviews. Smoking status was classiﬁed
s smokers (current smokers or smokers who had
uit for < 1 year), former smokers (those who had quit
or > 1 year) and non-smokers. All medications taken were
lso recorded. Antiplatelet agents, beta-blockers, nitrates,
alcium inhibitors, ACE inhibitors, diuretics, ARA II and
ipid-lowering treatments were taken into account for the
urposes of the study. In the REGICOR project, information
n the last two drugs was only available from 2001.
linical measurements
xaminations were performed by a team of trained nurses,
hysicians and interviewers, who used equivalent standard
uestionnaires and measurement methods in both surveys
20]. Anthropometrical measurements, including height and
ody weight were taken according to standardized proce-
ures. BMI was determined as weight divided by height
quared (kg/m2). Participants were classiﬁed into three
roups according to BMI: normal weight, BMI < 25 kg/m2;
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SCardiovascular risk factors in French and Spanish men with C
overweight, BMI≥ 25 and < 30; obese, BMI≥ 30. Blood pres-
sure was measured with a periodically calibrated mercury
sphygmomanometer in Spain and an automatic sphygmo-
manometer (OMRON 705 CP) in France. A cuff adapted
to the upper arm perimeter was selected for each par-
ticipant. Measurements were performed after at least a
5-minute rest. Two measurements were taken and the
lower value was recorded for the analysis. The cut-off
points to deﬁne hypertension followed the criteria pro-
posed in the Second Joint Task Force of European and
Other Societies on Coronary Heart Disease Prevention in
Clinical Practice [22] and in the 2000 recommendations
from the French Health Product Safety Agency [23]. These
guidelines were chosen as they were in current use in
Spain and France when the studies were carried out. The
guidelines recommended identical goals and methods for
cardiovascular prevention, except regarding the target goal
for cholesterol, which was lower in the European guide-
lines than in the French guidelines, as described in the
next paragraph. The following deﬁnitions were used for
hypertension and its treatment and control: history of hyper-
tension (when participants reported a previous diagnosis
or treatment for hypertension); real hypertension (history
of hypertension or systolic blood pressure≥ 140mmHg or
diastolic blood pressure≥ 90mmHg); treated hypertension
(patients with a history of hypertension on drug treatment);
controlled hypertension (systolic blood pressure < 140mmHg
and diastolic blood pressure < 90mmHg among treated
patients). Reference values were systolic blood pres-
sure < 130mmHg and diastolic blood pressure < 80mmHg for
diabetic patients.
Blood sample collection and biological
analyses
In both centres, blood was withdrawn after a 10—14-hour
fast, with less than 60 seconds duration, at least 2months
after acute myocardial infarction (6months in Spain).
Serum sample aliquots were stored at −80 ◦C. Brieﬂy, total
cholesterol, glucose and triglyceride concentrations were
determined enzymatically. HDL cholesterol was measured
as cholesterol after precipitation of apoprotein B-containing
lipoproteins with phosphotungstic-Mg++. LDL cholesterol was
calculated in both centres by the Friedewald equation when-
ever triglycerides were less than 3.4mmol/L [24] (389 and
544 individuals in France and Spain, respectively). Biolog-
ical measurements were performed in a core laboratory
in Barcelona for Spanish participants [25] and in a core
laboratory in the Toulouse University Hospital for French
subjects [26]. The cut-off points to deﬁne dyslipidaemia fol-
lowed the criteria used in the Second Joint Task Force of
European and Other Societies on Coronary Heart Disease Pre-
vention in Clinical Practice (LDL cholesterol≥ 3.0mmol/L
or HDL cholesterol≤ 1.0mmol/L) in Spain [22], and the
2000 recommendations from the French Health Product
Safety Agency (LDL cholesterol≥ 3.4mmol/L or HDL choles-
terol≤ 1.0mmol/L) in France [23].
Glucose metabolism disturbances were classiﬁed as fol-
lows: history of diabetes (participants already diagnosed by
a physician); impaired fasting glycaemia (fasting glycaemia
ranging from 6.1—6.9mmol/L in participants not previously
c
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iagnosed with diabetes); real diabetes (participants with
history of diabetes or with fasting glycaemia≥ 7mmol/L);
reated diabetes (patients with a history of diabetes under
rug treatment).
tatistical analyses
nitially, the analyses were performed on the whole sample,
hen age-stratiﬁed analyses were done (45—59 years; 60—74
ears). Continuous variables are summarized as means and
tandard deviations, and categorical variables are presented
s proportions. Student’s t test was used to compare means
f continuous variables. A logarithmic transformation was
one to compute the p-value for variables whose distribution
eparted from normal (i.e., glycaemia and triglycerides).
he 2-test was used to compare proportions. Statistical
nalysis was done with STATA software, version 9.2 (Stata
orp., College Station, TX, USA).
esults
e included 982 individuals aged 45—74 years (420 French
nd 562 Spanish participants). The mean age was 60 years.
he proportion of smokers was higher in Spanish partici-
ants whereas French subjects had a higher proportion of
ormer smokers (Table 1). The prevalence of obesity did not
iffer signiﬁcantly between France and Spain (Table 1). Sys-
olic and diastolic blood pressures were signiﬁcantly higher
n French participants in all age strata, and real hyperten-
ion occurred more frequently. In addition, among French
ubjects treated for hypertension there was signiﬁcantly
ower percentage of people with blood pressure below rec-
mmended levels (Table 1).
Average concentrations of total cholesterol, LDL choles-
erol and triglycerides were signiﬁcantly higher in French
articipants and the proportion of subjects with LDL choles-
erol > 3.4mmol/L was greater in France (Table 2). However,
hen dyslipidaemia was deﬁned according to the guidelines
sed in both countries (i.e., LDL cholesterol≥ 3.4mmol/L in
rance,≥ 3mmol/L in Spain, or HDL cholesterol≤ 1mmol/L)
he percentages of dyslipidaemic subjects were not signif-
cantly different between France and Spain. No signiﬁcant
ifference was observed in HDL cholesterol concentrations.
he percentage of participants with diagnosed diabetes
id not differ signiﬁcantly between the two countries, but
iabetic participants were treated signiﬁcantly more fre-
uently in France (Table 2).
French participants were treated more frequently with
ntiplatelet drugs, calcium inhibitors (especially younger
ubjects) and diuretics. The percentages of participants
eceiving lipid-lowering treatment or antihypertensive drugs
cting on the renin-angiotensin system (ACE-inhibitors or
RA II) were signiﬁcantly higher in Spain than in France
Table 3).
Fig. 1 shows the distribution of the number of major car-
iovascular risk factors per individual, among French and
panish participants. Real hypertension, dyslipidaemia (LDL
holesterol≥ 3.0mmol/L [Panel A] or≥ 3.4mmol/L [Panel
] or HDL≤ 1mmol/L), real diabetes, smoking and obesity
ere considered. Only 2.6% of the French and 2.8% of the
panish participants (Panel A) lacked all major cardiovascu-
ar risk factors (< 5% according to Panel B).
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Table 1 Prevalence of obesity, smoking and hypertension in France and Spain, by age.
45—59 years 60—74 years All
France (n = 222) Spain (n = 272) p France (n = 198) Spain (n = 290) p France (n = 420) Spain (n = 562) p
BMI (kg/m2) 27.2± 4.1 27.4± 4.0 0.718 27.0± 3.8 27.3± 3.8 0.370 27.1± 4.0 27.3± 3.8 0.395
Overweight and obesity 0.556 0.137 0.770
BMI < 25 kg/m2 67 (30.2) 65 (28.3) 58 (29.3) 70 (29.2) 125 (29.8) 135 (28.7)
25≤BMI < 30 kg/m2 100 (45.1) 115 (50.0) 106 (53.5) 111 (46.3) 206 (49.1) 226 (48.1)
BMI≥ 30 kg/m2 55 (24.8) 50 (21.7) 34 (17.2) 59 (24.6) 89 (21.2) 109 (23.2)
Smoking < 0.001 < 0.001 < 0.001
Non-smokers 48 (21.6) 36 (13.3) 46 (23.2) 67 (23.3) 94 (22.4) 103 (18.5)
Smokers 78 (35.1) 199 (73.7) 24 (12.1) 107 (37.2) 102 (24.3) 306 (54.8)
Former smokers 96 (43.2) 35 (13.0) 128 (64.7) 114 (39.6) 224 (53.3) 149 (26.7)
SBP (mmHg) 129± 20 112± 16 < 0.001 139± 22 115± 19 < 0.001 134± 21 114± 18 < 0.001
DBP (mmHg) 82± 11 66± 12 < 0.001 82± 10 66± 12 < 0.001 82± 10 66± 11 < 0.001
History of hypertension 82 (36.9) 107 (41.0) 0.362 85 (42.9) 162 (57.5) 0.002 167 (39.8) 269 (49.5) 0.003
Real hypertensiona 133 (59.9) 114 (42.5) < 0.001 147 (74.2) 172 (59.3) 0.001 280 (66.7) 286 (51.3) < 0.001
Treated hypertensionb 78 (95.1) 102 (98.1) 0.257 84 (100.0) 158 (97.5) 0.146 162 (97.6) 260 (97.7) 0.918
Controlled hypertensionc 38 (48.7) 70 (68.6) 0.007 30 (35.7) 118 (74.7) < 0.001 68 (42.0) 188 (72.3) < 0.001
Results are given as mean± standard deviation or number (%). BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure.
a History of hypertension or SBP≥ 140mmHg or DBP≥ 90mmHg (≥ 130/80mmHg in diabetic patients).
b Patients with a history of hypertension on drug treatment.
c SBP < 140mmHg and DBP < 90mmHg (< 130/80 in diabetic patients) among treated patients.
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Table 2 Prevalence of dyslipidaemia and diabetes in France and Spain, by age.
45—59 years 60—74 years All
France (n = 222) Spain (n = 272) p France (n = 198) Spain (n = 290) p France (n = 420) Spain (n = 562) p
Total cholesterol (mmol/L) 5.3± 1.1 4.9± 1.0 < 0.001 5.1± 1.2 4.6± 1.0 < 0.001 5.2± 1.1 4.7± 1.0 < 0.001
Total cholesterol≥ 4.9mmol/L 131 (59.0) 123 (45.4) 0.003 106 (53.5) 97 (33.5) < 0.001 237 (56.4) 220 (39.2) < 0.001
HDL cholesterol (mmol/L) 1.1± 0.3 1.1± 0.3 0.835 1.1± 0.3 1.1± 0.3 0.094 1.1± 0.3 1.1± 0.3 0.351
HDL cholesterol≤ 1.0mmol/L 129 (58.1) 142 (52.4) 0.205 90 (45.5) 141 (48.8) 0.469 219 (52.1) 283 (50.5) 0.618
LDL cholesterol (mmol/L) 3.3± 1.0 3.1± 1.0 0.053 3.2± 1.0 2.9± 0.9 < 0.001 3.2± 1.0 3.0± 1.0 < 0.001
LDL cholesterol≥ 3.0mmol/L 116 (59.2) 139 (53.98) 0.259 109 (56.5) 119 (41.6) 0.001 225 (57.8) 258 (47.4) 0.002
LDL cholesterol≥ 3.4mmol/L 82 (41.8) 94 (36.4) 0.242 72 (37.3) 83 (29.0) 0.057 154 (39.6) 177 (32.5) 0.026
Dyslipidaemiaa 147 (75.0) 196 (76.0) 0.812 127 (65.8) 195 (68.2) 0.586 274 (70.4) 391 (71.9) 0.632
Triglycerides (mmol/L) 2.2± 1.4 1.6± 0.9 < 0.001 1.7± 0.9 1.3± 0.6 < 0.001 1.9± 1.2 1.4± 0.7 < 0.001 e
Triglycerides≥ 2.0mmol/L 93 (41.9) 46 (17.0) < 0.001 47 (23.7) 32 (11.1) < 0.001 140 (33.3) 78 (13.9) < 0.001
Glycaemia (mmol/L) 6.2± 2.4 5.9± 1.8 0.293 6.1± 2.5 6.2± 2.2 0.370 6.2± 2.5 6.1± 2.1 0.940e
Impaired fasting glycaemiab 21 (11.3) 23 (10.5) 0.800 14 (8.8) 21 (9.1) 0.933 35 (10.1) 44 (9.8) 0.856
History of diabetes 43 (19.4) 60 (24.2) 0.207 62 (31.3) 73 (26.4) 0.237 105 (25.0) 133 (25.3) 0.907
Real diabetesc 78 (35.1) 81 (31.8) 0.436 87 (43.9) 97 (34.9) 0.046 165 (39.3) 178 (33.4) 0.060
Treated diabetesd 39 (90.7) 33 (68.8) 0.010 62 (100.0) 51 (76.1) < 0.001 101 (96.2) 84 (73.0) < 0.001
Results are given as mean± standard deviation or number (%). HDL, high-density lipoprotein; LDL, low-density lipoprotein.
a LDL cholesterol≥ 3.0mmol/L (Spain),≥ 3.4mmol/L (France) or HDL cholesterol≤ 1mmol/L.
b Glycaemia ranging from 6.1 to 6.9mmol/L in patients not previously diagnosed with diabetes.
c History of diabetes or glycaemia≥ 7mmol/L.
d Patients with a history of diabetes on drug treatment.
e Computed from log-transformed values.
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Figure 1. Number of cardiovascular risk factors per individual in
France and Spain, according to the Second Joint Task Force of Euro-
pean and Other Societies on Coronary Heart Disease Prevention in
Clinical Practice [22] (Panel A) or according to the 2000 recommen-
dations from the French Health Product Safety Agency [23] (Panel
B). p-values compare France and Spain. Cardiovascular risk fac-
tors taken into account: real hypertension (history of hypertension
or systolic blood pressure≥ 140mmHg or diastolic blood pres-
sure≥ 90mmHg [130/80mmHg in diabetic patients]); dyslipidaemia
(LDL cholesterol≥ 3.0mmol/L or HDL cholesterol≤ 1.0mmol/L
[Panel A]) or (LDL cholesterol≥ 3.4mmol/L or HDL choles-
terol≤ 1.0mmol/L [Panel B]); real diabetes (history of diabetes or
g 2
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vlycaemia≥ 7mmol/L; smoking; obesity (BMI≥ 30 kg/m ). GENES,
énétique et Environnement en Europe du Sud; REGICOR, Registre
ironi del Cor.
iscussion
ur results show a high prevalence of major cardiovascu-
ar risk factors in CHD patients both in Gerona (Spain) and
oulouse (France). Indeed, 97.4% of the French and 97.2%
f the Spanish participants presented with at least one of
he ﬁve following conditions: hypertension, dyslipidaemia,
iabetes, smoking or obesity. Previous international stud-
es have shown that the overall pattern of cardiovascular
isk factors exists irrespective of geographic origin [10,13].
espite similarities between Toulouse and Gerona areas
two regions that are close from a geographical point of
iew, located in South-West Europe and characterized by
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rCardiovascular risk factors in French and Spanish men with C
a low CHD incidence [15,16]), our study shows signiﬁcant
differences between the two countries regarding levels,
treatment and control of cardiovascular risk factors.
The most prevalent cardiovascular risk factor was dyslip-
idaemia in both regions. However, the lipid proﬁle in French
participants was more unfavourable than in Spanish sub-
jects and the use of lipid-lowering drugs was signiﬁcantly
lower in France. Consistent with the EUROASPIRE (European
Action on Secondary Prevention by Intervention to Reduce
Events) ﬁndings [11,12,14], lipid control was insufﬁcient
in the GENES and REGICOR studies: about half of the par-
ticipants did not reach the European goal established in
1998 for LDL cholesterol in secondary prevention of CHD
(guidelines used when patients were included) [22] and one-
third remained above the threshold proposed by the 2000
French guidelines (3.4mmol/L) [23]. The poorer control of
lipids observed in French patients compared with Spanish
patients is likely to be related to the less extensive use
of lipid-lowering drugs in France, although the EUROASPIRE
data have shown that poor lipid control may persist in CHD
patients, even after a dramatic improvement in the pres-
cription rates of lipid-lowering drugs [14].
An important ﬁnding of the study lies in the observation
that more than half of the CHD patients had low HDL choles-
terol (≤ 1mmol/L). The concentrations were much lower
than those described in other studies conducted among CHD-
free individuals living in Gerona and Toulouse areas [25,27].
It is well known that HDL cholesterol plays a key role in
the development of atherosclerosis, but raising HDL choles-
terol concentration still remains difﬁcult [28]. On the one
hand, lifestyle modiﬁcations (i.e., diet, exercise, weight
loss and smoking cessation) have been shown to have a
favourable impact on HDL cholesterol concentration; on
the other hand, evidence of the clinical efﬁcacy of HDL-
cholesterol-raising drugs is far less abundant than evidence
accumulated for statins [29]. Beyond LDL cholesterol con-
trol, raising HDL cholesterol is essential to reduce residual
risk in CHD patients.
Hypertension was very common in both populations. The
proportion of treated patients among those who reported
a previous history of hypertension was close to 100%. Nev-
ertheless, blood pressure control remained poor, especially
in French participants. This failure has been described
extensively in other studies [11,12,14,19] and is generally
attributed to low-dose treatment prescriptions, inadequate
up-titration of doses and poor patient compliance [14], but
could also be related to severe hypertension before treat-
ment. Despite the availability of numerous antihypertensive
drugs, blood pressure control is still challenging in CHD
patients.
Diabetes increases markedly the risk of CHD and non-fatal
recurrent coronary events in patients with clinically estab-
lished CHD [30]. One-quarter of patients enrolled in the
GENES and REGICOR studies were known diabetics and about
an additional 10% (14% in France and 8% in Spain) had fast-
ing plasma glucose concentrations≥ 7mmol/L, which could
be compatible with a diagnosis of diabetes. Consequently,
more than one-third of patients were potentially affected
by glucose disturbances, and thus should be considered at
high risk of recurrence.
According to a previous study, CHD events are attributed
largely to smoking in Spanish men [31]. Although the design
d
a
l
g
t87
f our study did not allow us to compute population-
ttributable risk fractions, our results show that smoking is
xtremely prevalent in CHD patients aged less than 60 years,
ith very few people achieving smoking cessation. In older
ge groups (60—74 years), a greater proportion of patients
ave quit, although 37% remained current smokers. These
esults highlight the need to reinforce all measures that
ould help patients to quit smoking permanently, in line
ith all current recommendations on cardiovascular preven-
ion [32]. From a population point of view, laws aimed at
orbidding smoking in public areas have been strengthened
ecently in France and Spain and could have a favourable
mpact on the prevalence of smoking in CHD patients.
No difference was found in the percentages of French
nd Spanish participants who were treated with a com-
ination of the four drugs recommended in secondary
revention: statins, antiplatelet agents, beta-blockers and
CE-inhibitors. This drug combination has been shown to
mprove survival in high-risk patients with CHD [33] and is
ecommended by the European guidelines for cardiovascu-
ar prevention [22,32], although the role of ACE-inhibitors
n CHD patients without a history of heart failure is still
ontroversial [33—35]. According to a previous study, heart
ailure is the main determinant of the use of ACE-inhibitors
n France [9].
Finally, the proportion of non-smoking CHD patients
ho were free of hypertension, dyslipidaemia, diabetes
nd obesity was very small (< 3%) in both countries, sug-
esting that traditional risk factors remain central in the
evelopment of atherothrombosis in low-risk populations.
owever, our results also point out differences in the distri-
ution, treatment and control of risk factors that should be
aken into consideration to adapt prevention programmes to
ocal characteristics. Causes of CHD are widely dependent
n socioeconomic and cultural factors, which determine
nhealthy lifestyles, and on healthcare systems, which
etermine patient management [1,32]. It is also likely that
ifferences between France and Spain in coronary patients’
isk factors reﬂect differences in the background population
ardiovascular risk proﬁle. Accordingly, two previous stud-
es conducted in Spanish and French subjects recruited from
he general population suggested that there are lower smok-
ng rates and higher total cholesterol, LDL cholesterol and
riglyceride concentrations in the general French population
ompared with the general Spanish population [25,36]. We
escribe in our present paper similar disparities between
rench and Spanish coronary patients.
imitations
everal points should be discussed regarding our analyses
nd results. First, the GENES study included individuals with
rst or recurrent acute myocardial infarction, whereas par-
icipants in the REGICOR study were all recruited after a
rst acute myocardial infarction. We believe these different
ecruitment strategies may have contributed to observed
ifferences in the control of risk factors between France
nd Spain, as patients with a history of recurrent events are
ikely to have a more severe risk factor proﬁle. However,
oals for cardiovascular prevention do not differ according
o the number of acute events presented previously by the
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atient. When necessary, in cases of poor risk factor pro-
le, more intensive management should be provided so that
very patient in a situation of secondary prevention achieves
he recommended goals.
Second, the period of recruitment was slightly differ-
nt in the two studies (2001—2004 for the GENES study and
995—2004 for the REGICOR study, although participants in
he REGICOR study were recruited mainly after 2001). This
ap in the recruitment periods may have affected treatment
atterns. For instance, the rate for the use of antiplatelet
rugs was low in the Spanish sample, but should be inter-
reted as a mean proportion obtained from recent and older
eriods and reﬂecting the progressive implementation of the
uidelines on cardiovascular prevention that were published
n 1998. Even so, the use of antiplatelet drugs is very low in
he Spanish sample and may be related to the inclusion of
atients aged greater than 70 years, for whom antiplatelet
rugs may have been underprescribed before the end of the
990s.
Third, the elapsed time between the occurrence of the
yocardial infarction and examination in the study was
ifferent in Spanish and French participants, with shorter
elays in Spain. Given that drug prescription, adhesion to
reatment and, consequently, control of risk factors are
robably better in patients who have presented recently
ith an acute coronary event, differences in delays may
ave increased differences in the management of risk fac-
ors between France and Spain. However, recommendations
or smoking cessation and control of blood pressure, gly-
aemia and cholesterol are identical for patients with recent
yocardial infarction and for those with an older history,
nd drug use should not vary with the time elapsed since
he acute syndrome.
onclusion
he strength of our present study lies in the comparison of
wo countries with different lifestyle habits, dietary pat-
erns and healthcare systems, but relatively similar CHD
ncidence. Comparisons were based on extensive clinical and
iological evaluations of cardiovascular risk factors. We have
ointed out higher smoking rates, better blood pressure con-
rol and better lipid proﬁles in Spain compared with France.
his may reﬂect differences in the background proﬁle of risk
actors in the general population. Regarding lipids, differ-
nces may also be related to the implementation of a lower
ecommended goal for cholesterol control and greater use of
ipid-lowering drugs in Spain at the beginning of the 2000s,
hen most of the study recruitment took place.
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